Pharming's promotion to the AMX mid-cap index in September 2025 reflects the company's strong growth momentum. The company is focused on executing significant commercial and pipeline catalysts to develop into a leading global rare disease company.
Cyborg Score Rationale
Pharming demonstrates strong growth momentum with its September 2025 promotion to the Euronext AMX mid-cap index. The company has a focused rare disease strategy with key pipeline catalysts including leniolisib for primary immunodeficiencies, though it faces regulatory complexities in bringing novel therapies to market.
Top Insights
Promoted to AMX mid-cap index (September 2025) signaling strong commercial and financial momentum
Leniolisib in accelerated FDA review pathway for pediatric rare immunodeficiency (APDS)
Dual-listed on Euronext Amsterdam (PHARM) and NASDAQ (PHAR) expanding investor accessibility
Global commercial footprint across 30+ markets with focused rare disease expertise
Named Competitors
Berinert/C1-esterase inhibitor — Plasma-derived C1-esterase inhibitor for acute HAE attacks
Cinryze — C1-esterase inhibitor concentrate for hereditary angioedema prophylaxis
Kallikrein inhibitors — Alternative mechanism for HAE and rare disease management
Recent Developments
(February 2026) FDA Complete Response Letter for leniolisib indicating regulatory pathway challenge
(December 2025) Participation in Oppenheimer Movers in Rare Disease Summit showcasing HAE market leadership
(September 2025) Promotion to Euronext AMX index reflecting mid-cap market capitalization milestone
(January 2026) Full-year 2025 preliminary revenue announcement with organizational restructuring
Open the full interactive Pharming Group N.V. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.